nach oben

Zeitschrift für Gerontologie und Geriatrie

Erschienen in:

01.08.2013 | CME Zertifizierte Fortbildung

Lipidsenkende Therapie bei geriatrischen Patienten

verfasst von: Prim. Univ.-Prof. Dr. M. Lechleitner

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Kardiovaskuläre Erkrankungen stellen auch bei älteren Menschen die häufigste Todesursache dar. Invasive diagnostische und therapeutische Interventionen werden in zunehmendem Maß bei älteren Patienten durchgeführt, um die Funktionalität und damit eine gute Lebensqualität zu erhalten. Präventivmedizinische Maßnahmen, wie die lipidsenkende Therapie, reduzieren die kardiovaskuläre Ereignisrate und sind deshalb auch bei älteren Menschen von Bedeutung. Unter Statintherapie sollten hinsichtlich des Nebenwirkungsprofils Arzneimittelinteraktionen wie auch die Myopathie besonders beachtet werden. Bezüglich der Einflussnahme der Statine auf die kognitive Leistungsfähigkeit liegen zum Teil divergente Ergebnisse vor. Retrospektive Analysen weisen auf ein erhöhtes Risiko zur Manifestation eines Typ-2-Diabetes in Risikogruppen hin. Die Indikationsstellung zur Statintherapie sollte das Risikoprofil und die individuelle Situation des älteren Patienten berücksichtigen.

Vorheriger Artikel Translationale Forschung in der Geriatrie?

Nächster Artikel Journal Club

Afilalo J, Duque G, Steele R et al (2008) Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol 51:37–45PubMedCrossRef

Alonzo CB (2011) Myths and facts concerning the use of statin in very old patients. Cardiovasc Haematol Disord Drug Targets 11:17–23CrossRef

American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127:143–152CrossRef

Aronow WS (1996) Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 77:864–866PubMedCrossRef

Baigent C, Keech A, Kearny PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised statin trials. Lancet 366:1267–1278PubMedCrossRef

Berr JD, Dyer A, Cai X et al (2012) Lifetime risk of cardiovascular diseases. N Engl J Med 366:321–329CrossRef

Berthold HK, Gouni-Berthold I (2011) Lipid-lowering drug therapy in elderly patients. Curr Pharm Dis 17:877–893CrossRef

Bottorff MB (2006) Statin safety and drug interactions: clinical significance. Am J Cardiol 97:276–312CrossRef

Boyd CH, Vollenweider D, Puman MA (2012) Informing evidence-based decision-making for patients with comorbidity: availability of increasing information in clinical trials for chronic disease. PLoS ONE (E-pub ahead of print)

10.

Carriere I, Dupuy AM, Lacroux A et al (2008) Biomarkers of inflammation and malnutrition associated with early death in healthy elderly people. J Am Geriatr Soc 56:840–846PubMedCrossRef

11.

Casiglia E, Mazza A, Tikhoff V et al (2003) Total cholesterol and mortality risk in the elderly. J Int Med 254:353–364CrossRef

12.

Cholesterol Treatment Trialists (CTT) Collaborators (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–590

13.

Choskshi NP, Messerli FH, Sutin D et al (2012) Appropriateness of statin in patients ages ≥ 80 years and comparison to other age groups. Am J Cardiol 110:1477–1481CrossRef

14.

Corti MC, Guralnik JM, Salive ME et al (1997) Clarifying the direct relation between total cholesterol levels and deaths from coronary heart disease in older persons. Ann Intern Med 126:753–760PubMedCrossRef

15.

Dobkin BH (2005) Underappreciated statin-induced myopathy weakness causes disability. Neurorehabil Neural Repair 19:259–263PubMedCrossRef

16.

Dzien A, Winner H, Theurl E et al (2013) Fat-free mass and fasting glucose values in patients with and without statin therapy assigned to age groups between < 60 and > 75 years. Obes Facts 6:9–16PubMedCrossRef

17.

Farnier M, Bruckert E (2012) Severe familial hypercholesterolaemia: current and future management. Arch Cardiovasc Dis 105:656–665PubMedCrossRef

18.

Farzadfar F, Finucane MM, Danaei G et al (2011) National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 377:578–586PubMedCrossRef

19.

Ferrara A, Barrett-Connor E, Shan J (1997) Total, LDL, and HDL-cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984–1994. Circulation 96:37–48PubMedCrossRef

20.

Gargiulo G, Giugliano G, Brevetti L, Sannino A et al (2012) Use of statis in lower extremity artery disease: a review. BMC Surg 12(Suppl 1):S15PubMedCrossRef

21.

Ghosh S, Aronow WS (2003) Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatement. J Gerontol A Biol Sci Med Sci 58:M432–M435PubMedCrossRef

22.

Goldstein MR, Mascitelli L (2013) Do statins cause diabetes? Curr Diab Rep (E-pub ahead of print)

23.

Gotto AM Jr (2007) Statintherapy and the elderly. SAGE advice? Circulation 115:681–683PubMedCrossRef

24.

Gotto AM Jr, Moon JE (2012) Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 110:3A–14APubMedCrossRef

25.

Grundy SM, Cleeman JI, Rifkinf BM et al (1999) Cholesterol lowering in the elderly population. Arch Intern Med 159:1670–1678PubMedCrossRef

26.

Grundy SM, Cleeman JL, Merz NB, Brewer B et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Atherosclerosis 24:e149–e161

27.

Heart Protection Study Collaborative Group (2011) Effects on 11-year mortality and morbidity for lowering LDL-cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378:2013–2020

28.

Huisa BN, Stemer AB, Zivin JA (2010) Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag 6:229–236PubMed

29.

Hunt D, Young P, Simes J et al (2001) Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in young patients: results from the LIPID trial. Ann Intern Med 134:931–940PubMedCrossRef

30.

Jackson R, Lawes CMM, Bennett DA et al (2005) Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 365:434–441PubMed

31.

Jick H, Zornberg GL, JIck SS et al (2000) Statins and the risk of dementia. Lancet 356:1627–1630PubMedCrossRef

32.

Johnman C, Mackay DF, Olroyd K, Pell JP (2013) Quality of life following percutaneous coronary interventions in octogenerians: a systematic review. Heart (E-pub ahead of print)

33.

Kanter MM, Kris-Etherton PM, Fernandez ML et al (2012) Exploring the factors that affect blood cholesterol and heart disease: is dietary cholesterol as bad for you as history leads us to believe? Adv Nutr 3:711–717PubMedCrossRef

34.

Kini AS, Baber U, Kovacic JE, Limaye A et al (2013) Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trail. J Am Coll Cardiol (E-pub ahead of print)

35.

Knoops KT, Groot LC de, Kromhout D et al (2004) Mediterranean diet, life-style factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA 292:1433–1439PubMedCrossRef

36.

Leung A, Schaeffer EW, Tempelhof MV, Stone NJ (2012) Emphasizing statin safety in the hospitalized patient: a review. Am J Med 125:845–853PubMedCrossRef

37.

Manktelow BN, Potter JF (2009) Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 8:CD002091

38.

Marcum ZA, Vandegried JP, Linnebur SA (2012) FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 10:264–271PubMedCrossRef

39.

McGuiness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev 15:CD003160

40.

Nash DT (2003) Statins. Evidence of effectiveness in older patients. Geriatrics 58:39–42

41.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High blood Cholesterol in adults (Adult Treatment Panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults – final report. Circulation 106:3143–3421

42.

Ni Chroinin D, Asplund K, Asberg S, Callaly S et al (2013) Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 44:448–456CrossRef

43.

Padala KP, Padala PR, McNeilly DP et al (2012) The effect of HMG-Co-A reductase inhibitors on cognition in patients with Alzheimer’s disease: a prospective withdrawl and rechallenge pilot study. Am J Geriatr Pharmacother 10:296–302PubMedCrossRef

44.

Patel AB, Kostis JB, Wilson AC et al (2008) Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. Stroke 39:1084–1089PubMedCrossRef

45.

Perk J, DeBacker G, Gohlke H et al (2012) European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 33:1635–1701PubMedCrossRef

46.

Petersen LK, Christensen K, Kragstrup J (2010) Lipid lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80 + year olds. Age Ageing 39:674–680PubMedCrossRef

47.

Prospective Studies Collaboration, Lewington S, Whitlock G et al (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 37:1829–1839

48.

Redelmeier DA, Thiruchelvam D, Danman N (2008) Delirium after elective surgery among elderly patients taking statins. CMAJ 179:645–652PubMed

49.

Rockwood K, Kirkland S, Hogan DB, Mac Knight C et al (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59:223–227PubMedCrossRef

50.

Saely CH, Drexel H (2013) Is type 2 diabetes really a coronary heart disease risk equivalent? Vascul Pharmacol (E-pub ahead of print)

51.

Sampson U, Linton MF, Fazio S (2011) Are statins diabetogenic? Curr Opin Cardiol 26:342–347PubMedCrossRef

52.

Sheperd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk for vascular disease (PROSPER). A randomised controlled trial. Lancet 360:1623–1630CrossRef

53.

Sparks DL, Kryscio RJ, Sabbagh MN et al (2008) Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 5:416–421PubMedCrossRef

54.

Taylor F, Huffmann MD, Macedo AF et al (2013) Statins for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev 1:CD004816PubMed

55.

Terry DF, Evans JC, Pencina MJ, Murabito JM et al (2007) Characteristics of Framingham offspring participants with long-lived parents. Arch Intern Med 167:438–444PubMedCrossRef

56.

Thompson PD, Clarkson P, Karas RH (2003) Statin associated myopathy. JAMA 13:1681–1690CrossRef

57.

Upmeier E, Korhonen MJ, Melin-Salmivaara A, Huupponen R (2013) Statin use among older Fins stratified according to cardiovascular risk. Eur J Clin Pharmacol 69:261–267PubMedCrossRef

58.

Vliet P van, Water W van de, Craen AJ de, Westendorp RG (2009) The influence of age on the association between cholesterol and cognitive function. Exp Gerontol 44:112–122PubMedCrossRef

59.

Vischer UM, Frangos E, Graf C et al (2012) The prognostic significance of malnutrition as assessed by the Mini Nutritional Assessment (MNA) in older hospitalized patients with heavy disease burden. Clin Nutr 31:113–117PubMedCrossRef

60.

Vogt A, Nieczaj R, Thomas HP et al (2002) Primary and secondary prevention in dyslipidemia in the elderly. Ther Umsch 59:341–344PubMedCrossRef

61.

Volkert D, Saeglitz C, Gueldenzoph H et al (2010) Undiagnosed malnutrition and nutrition-related problems in geriatric patients. J Nutr Health Aging 14:387–392PubMedCrossRef

62.

Volpato S, Ble A, Metter EJ et al (2008) High-density lipoprotein cholesterol and objective measures of lower extremity performance in older nondisabled persons: the InChianti study. J Am Geriatr Soc 56:621–629PubMedCrossRef

63.

Weijnberg MP, Feskens EJ, Kromhout D (1996) Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow up. The Zutphen Elderly Study. Am J Epidemiol 143:151–158CrossRef

64.

Weverling-Rijnsburger AW, Jonkers IJ, Exel E van et al (2003) High-density vs low density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 163:1549–1554PubMedCrossRef

65.

Yusuf S, Lonn E, Bosch J (2009) Lipid lowering for primary prevention. Lancet 373:1152–1155PubMedCrossRef

66.

Cholesterol Treatment Trialists‘ (CTT) Collaboration et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670–1681CrossRef

67.

Brugts JJ, Yetgin T, Hoeks SE et al (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338:b2376PubMedCrossRef

68.

Lewis SJ, Moye LA, Sacks FM et al (1998) Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129:681–689PubMedCrossRef

69.

Gränsbo K, Melander O, Wallentin L et al (2010) Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 55:1362–1369PubMedCrossRef

Titel: Lipidsenkende Therapie bei geriatrischen Patienten
verfasst von: Prim. Univ.-Prof. Dr. M. Lechleitner
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Zeitschrift für Gerontologie und Geriatrie / Ausgabe 6/2013
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI: https://doi.org/10.1007/s00391-013-0516-6

Springerpflege

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Alternsumkehr und Lebensspannenverlängerung

Der Querschnittsbereich Q7 „Medizin des Alterns und des alten Menschen“ an der Charité – Universitätsmedizin Berlin

Bewegungsparcours, Sturzrisiko und gesundheitsbezogene Lebensqualität

Genderaspekte bei kardiovaskulären Krankheiten

Mitteilungen der DGG

Psychische Erkrankungen bei Frauen und Männern im Alter